葡萄糖稳态
内分泌学
内科学
信号转导
平衡
受体
胰高血糖素
生物
胰高血糖素受体
2型糖尿病
G蛋白偶联受体
葡萄糖摄取
糖尿病
细胞生物学
胰岛素
医学
胰岛素抵抗
作者
Mario Rossi,Lu Zhu,Sara M. McMillin,Sai P. Pydi,Shanu Jain,Lei Wang,Yinghong Cui,Regina J. Lee,Amanda Cohen,Hideaki Kaneto,Morris J. Birnbaum,Yanling Ma,Yaron Rotman,Jie Liu,Travis J. Cyphert,Toren Finkel,Owen P. McGuinness,Jürgen Wess
摘要
An increase in hepatic glucose production (HGP) is a key feature of type 2 diabetes. Excessive signaling through hepatic Gs-linked glucagon receptors critically contributes to pathologically elevated HGP. Here, we tested the hypothesis that this metabolic impairment can be counteracted by enhancing hepatic Gi signaling. Specifically, we used a chemogenetic approach to selectively activate Gi-type G proteins in mouse hepatocytes in vivo. Unexpectedly, activation of hepatic Gi signaling triggered a pronounced increase in HGP and severely impaired glucose homeostasis. Moreover, increased Gi signaling stimulated glucose release in human hepatocytes. A lack of functional Gi-type G proteins in hepatocytes reduced blood glucose levels and protected mice against the metabolic deficits caused by the consumption of a high-fat diet. Additionally, we delineated a signaling cascade that links hepatic Gi signaling to ROS production, JNK activation, and a subsequent increase in HGP. Taken together, our data support the concept that drugs able to block hepatic Gi-coupled GPCRs may prove beneficial as antidiabetic drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI